Article

Online CME: Mitochondria: An Emerging Therapeutic Focus in Alzheimer's

Check out these three, online CME activities on Alzheimer's disease

Credits: 2.00

Fee: None

Expires: August 31, 2011

Multimedia: None

With mitochondira representing an emerging therapeutic focus in Alzheimer’s disease research, as more and more evidence shows the cell components might play a key role in aging and neurodegenerative disease, this course reviews current Alzheimer’s disease treatments and their mechanisms of action; provides and overview of the suggested role played by mitochondria in aging and neurodegenerative diseases; and explores “recent evidence regarding the efficacy of an agent targeting the mitochondria in the treatment of Alzheimer's disease.”

Click here, enter "Alzheimer's disease" in the search window at the landing page, and select your profession to access this third-party resource.

More online, Alzheimer's disease CME ativities:

  • Do You Know Who I Am? A Look at the Devastating Effects of Alzheimer's Disease - Strategies for Early Recognition and Treatment
  • Exploring the Potential of Novel Mechanisms in the Treatment of Alzheimer's and Huntington's Diseases
  • Improving the Quality of Patient Screening, Timely Diagnosis, and Institution of Therapy for Alzheimer’s Disease Among Minority Populations in the Community and Long-Term Care Settings
Related Videos
Parent Stress Reduces Over Time When Weaning Child Off Tube Feeding with Hide Okuno, MS
Akif Shameem, MD: Generalized Anxiety Disorder Linked to Longer Hospitals in Children with IBD
Jonathan Meyer, MD: Cognitive Gains, Dopamine-Free Schizophrenia Treatment with Xanomeline Trospium Chloride
Chelsie Monroe: Challenges Clinicians Should Consider When Prescribing Muscarinic Modulators for Schizophrenia
Thumbnail for schizophrenia special report around approval of Cobenfy.
Thumbnail for schizophrenia special report around approval of Cobenfy.
Thumbnail for schizophrenia special report around approval of Cobenfy.
Thumbnail for schizophrenia special report around approval of Cobenfy.
© 2024 MJH Life Sciences

All rights reserved.